Celgene Corp. (CELG) on Tuesday said it has agreed to buy Receptos Inc. (RCPT) for about $7.2 billion in cash, thus enhancing its Inflammation & Immunology portfolio. Moving ahead, Celgene lifted its financial outlook for 2020 as a result of the acquisition.